Comprehensive Molecular Studies in 88 Japanese Patients With Congenital Hypogonadotropic Hypogonadism

In 88 Japanese CHH patients, only 39% had a confirmed pathogenic variant; the rest showed hallmarks of multi-gene inheritance

Journal: The Journal of Clinical Endocrinology and Metabolism | Published: 2026-03-17 | Type: Journal Article | PMID: 41042998 Authors: Tanikawa W et al. (Hamamatsu University School of Medicine; National Research Institute for Child Health and Development, Tokyo) Funding/COI: Japan Agency for Medical Research and Development. COI not disclosed.

Summary

Congenital hypogonadotropic hypogonadism (CHH) — failure of the hypothalamic-pituitary axis to trigger puberty, caused by deficient GnRH secretion or action — is commonly framed as a single-gene disorder, but this study pushes back on that framing. Of 88 Japanese patients screened with gene panel analysis and whole-exome sequencing, only 34 (39%) had a clearly pathogenic or likely pathogenic variant. The remaining 54 patients without a smoking-gun variant still accumulated significantly more rare variants across CHH-related genes than 100 healthy controls, pointing toward oligogenic or multifactorial causation rather than a missed monogenic diagnosis.

Claims

• 27 pathogenic/likely pathogenic variants were identified across 34 of 88 patients (38.6%): 30 via gene panel analysis, 4 additional via WES
• FGFR1 was the most frequently implicated gene: 14 variants in 15 patients
• ANOS1 contributed 6 variants in 7 patients; PROKR2 contributed 2 variants in 8 patients
• ZNF462 is flagged as a previously unrecognized CHH gene, with 1 variant in 1 patient
• 12 additional genes — including SEMA4D and CDH2, both plausible given the CHH molecular network — carried potentially disease-related variants
• In the 54 patients with no confirmed pathogenic variant, the frequency of oligogenicity was significantly higher and the count of rare variants per individual was significantly larger compared to 100 controls (specific p-values not reported in abstract)
• One patient carried 2 pathogenic variants simultaneously

Study Quality

This is a single-center Japanese cohort study using a two-tier genetic screening approach: gene panel analysis (GPA) for 14 established CHH genes in all 88 patients, followed by whole-exome sequencing in the 58 who came up negative. WES was initially restricted to 41 candidate genes and then expanded — a reasonable adaptive design for a rare condition, though the staged approach introduces some complexity in interpreting the negative WES results. Variant pathogenicity was assessed using ACMG/AMP criteria and cross-referenced against ClinVar, which is the current standard. The comparison of oligogenic burden in CHH patients vs. 100 controls is a valid analytical move, though the study doesn't report exact test statistics in the abstract.

The sample size (88 patients) is substantial for CHH, which has a prevalence of roughly 1 in 4,000–10,000 — this is a real genetic study, not a case series. The limitation is population specificity: Japanese cohorts have distinct allele frequencies from European or Middle Eastern populations where most CHH genetics literature originates, which is both a contribution (expands global data) and a caveat (findings may not generalize).

Red Flags

• No functional validation for the novel ZNF462 variant or the 12 candidate-gene variants — statistical association and network plausibility are not the same as causation
• COI not disclosed; industry entanglement cannot be ruled out
• Exact statistical test results (odds ratios, p-values, confidence intervals) for the oligogenicity comparison are absent from the abstract
• Single-ethnicity cohort limits generalizability; allele frequencies in Japanese populations differ meaningfully from other groups
• WES was initially limited to a pre-selected 41-gene panel, meaning truly novel causal genes outside that list could still be missed
• One-third of patients remain genetically unexplained even after WES

Strengths

• Largest Japanese CHH molecular genetics cohort to date
• Two-tier methodology (GPA then WES) is appropriately staged and resource-efficient
• ACMG/AMP pathogenicity criteria and ClinVar cross-referencing applied systematically
• Identification of ZNF462 as a candidate gene adds a concrete hypothesis for follow-up
• Oligogenic burden analysis against controls is methodologically sound and strengthens the multifactorial argument
• Government-funded (Japan Agency for Medical Research and Development), reducing direct industry conflict risk

Verdict

This paper does something useful: it uses a real cohort to demonstrate that the "find the one broken gene" approach to CHH leaves most patients unexplained, and it provides statistical evidence that those unexplained patients aren't simply genetic blanks — they carry a measurably heavier load of rare variants across CHH-related pathways. The ZNF462 finding is speculative at n=1 and needs functional work before it earns a place in diagnostic panels. But the core argument — that oligogenic inheritance is common in CHH and that a negative gene panel doesn't mean no genetic cause — is well-supported and clinically relevant for how genetic counselors frame CHH diagnoses. Worth reading if you work in reproductive endocrinology or rare disease genetics.